

20. (New) A method according to claim 17 in which elevated CT-1 levels are indicative of the initiation or onset of cardiac hypertrophy.

21. (New) A method according to claim 18 in which elevated CT-1 levels are indicative of the initiation or onset of cardiac hypertrophy.

22. (New) A method according to claim 19 in which elevated CT-1 levels are indicative of developing cardiac hypertrophy.

23. (New) A method according to claim 17 in which the human bodily fluid sample comprises whole blood, plasma, serum, urine, tears, sputum, saliva or synovial fluid.

24. (New) A method according to claim 17 in which the *in vitro* assay is arranged to detect CT-1 protein or fragments thereof.

25. (New) A method according to claim 24 in which the *in vitro* assay comprises radio immuno assay or enzyme-linked immunosorbant assay.

26. (New) A method according to claim 17 in which the *in vitro* assay is arranged to detect CT-1 nucleic acid or fragments thereof.

27. (New) A method according to claim 26 in which the *in vitro* assay comprises hybridisation, sequencing or amplification techniques.

28. (New) A method according to claim 17 further comprising an *in vitro* assay for an additional marker.

29. (New) A method according to claim 28 in which the additional marker is selected from ANF, oncostatin M, ciliary neurotrophic factor and leukaemia inhibiting factor.

30. (New) Use of a method according to claim 17 to determine human subjects who should be treated for hypertension.